🇺🇸 FDA
Pipeline program

RLY-2608

RLY-2608-201

Phase 2 small_molecule active

Quick answer

RLY-2608 for PIK3CA-Related Overgrowth Spectrum (PROS) is a Phase 2 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Relay Therapeutics
Indication
PIK3CA-Related Overgrowth Spectrum (PROS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials